Browse HAVCR2

Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein Cell junction Note=Localizes to the immunological synapse between CD8+ T-cells and target cells.
Domain PF07686 Immunoglobulin V-set domain
Function

Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed:24825777). Regulates macrophage activation (PubMed:11823861). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed:14556005). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse (PubMed:24337741, PubMed:26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed:24838857). Receptor for LGALS9 (PubMed:16286920, PubMed:24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed:23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF-alpha. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed:22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed:22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock (By similarity).

> Gene Ontology
 
Biological Process GO:0001771 immunological synapse formation
GO:0001773 myeloid dendritic cell activation
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001911 negative regulation of leukocyte mediated cytotoxicity
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002228 natural killer cell mediated immunity
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002281 macrophage activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:0002347 response to tumor cell
GO:0002366 leukocyte activation involved in immune response
GO:0002418 immune response to tumor cell
GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002423 natural killer cell mediated immune response to tumor cell
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002461 tolerance induction dependent upon immune response
GO:0002507 tolerance induction
GO:0002519 natural killer cell tolerance induction
GO:0002643 regulation of tolerance induction
GO:0002652 regulation of tolerance induction dependent upon immune response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002716 negative regulation of natural killer cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002826 negative regulation of T-helper 1 type immune response
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002835 negative regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002838 negative regulation of immune response to tumor cell
GO:0002855 regulation of natural killer cell mediated immune response to tumor cell
GO:0002856 negative regulation of natural killer cell mediated immune response to tumor cell
GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002859 negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007565 female pregnancy
GO:0008037 cell recognition
GO:0009306 protein secretion
GO:0009988 cell-cell recognition
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030101 natural killer cell activation
GO:0030885 regulation of myeloid dendritic cell activation
GO:0030886 negative regulation of myeloid dendritic cell activation
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032606 type I interferon production
GO:0032607 interferon-alpha production
GO:0032609 interferon-gamma production
GO:0032612 interleukin-1 production
GO:0032623 interleukin-2 production
GO:0032632 interleukin-3 production
GO:0032633 interleukin-4 production
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032647 regulation of interferon-alpha production
GO:0032649 regulation of interferon-gamma production
GO:0032652 regulation of interleukin-1 production
GO:0032663 regulation of interleukin-2 production
GO:0032672 regulation of interleukin-3 production
GO:0032673 regulation of interleukin-4 production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032687 negative regulation of interferon-alpha production
GO:0032689 negative regulation of interferon-gamma production
GO:0032703 negative regulation of interleukin-2 production
GO:0032712 negative regulation of interleukin-3 production
GO:0032715 negative regulation of interleukin-6 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032722 positive regulation of chemokine production
GO:0032729 positive regulation of interferon-gamma production
GO:0032732 positive regulation of interleukin-1 production
GO:0032753 positive regulation of interleukin-4 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032814 regulation of natural killer cell activation
GO:0032815 negative regulation of natural killer cell activation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0034138 toll-like receptor 3 signaling pathway
GO:0034154 toll-like receptor 7 signaling pathway
GO:0034162 toll-like receptor 9 signaling pathway
GO:0036301 macrophage colony-stimulating factor production
GO:0038061 NIK/NF-kappaB signaling
GO:0042088 T-helper 1 type immune response
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042116 macrophage activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042742 defense response to bacterium
GO:0043030 regulation of macrophage activation
GO:0043032 positive regulation of macrophage activation
GO:0043410 positive regulation of MAPK cascade
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044706 multi-multicellular organism process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045785 positive regulation of cell adhesion
GO:0045824 negative regulation of innate immune response
GO:0045953 negative regulation of natural killer cell mediated cytotoxicity
GO:0046651 lymphocyte proliferation
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050777 negative regulation of immune response
GO:0050830 defense response to Gram-positive bacterium
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0051047 positive regulation of secretion
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0060135 maternal process involved in female pregnancy
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0071611 granulocyte colony-stimulating factor production
GO:0071655 regulation of granulocyte colony-stimulating factor production
GO:0071656 negative regulation of granulocyte colony-stimulating factor production
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0098542 defense response to other organism
GO:1900424 regulation of defense response to bacterium
GO:1900425 negative regulation of defense response to bacterium
GO:1900426 positive regulation of defense response to bacterium
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:1901256 regulation of macrophage colony-stimulating factor production
GO:1901257 negative regulation of macrophage colony-stimulating factor production
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903532 positive regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1904467 regulation of tumor necrosis factor secretion
GO:1904469 positive regulation of tumor necrosis factor secretion
GO:1904951 positive regulation of establishment of protein localization
GO:1990774 tumor necrosis factor secretion
GO:2000520 regulation of immunological synapse formation
GO:2000521 negative regulation of immunological synapse formation
GO:2001188 regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001189 negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
Molecular Function -
Cellular Component GO:0001772 immunological synapse
GO:0005769 early endosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-451927: Interleukin-2 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HAVCR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HAVCR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25614966MelanomaInhibit immunity (T cell function)Thus, our data identify an IL-27/NFIL3 signalling axis as a key regulator of effector T-cell responses via induction of Tim-3, IL-10 and T-cell dysfunction.
25363763Colorectal CarcinomaInhibit immunity (T cell function)Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models.
22505239Hepatocellular CarcinomaInhibit immunity (T cell function)Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
29316433Breast carcinomaInhibit immunityHere we evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast cancer and identified expression of TIM-3 as a target for therapy.
24667641Metastatic MelanomaInhibit immunity (T cell function)In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8? TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8? lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137).
28585539Colorectal Carcinoma; Melanoma; Bladder CarcinomaInhibit immunity (T cell function)During this process, we find that the co-expression of Tim-3 and PD-1 marks functionally exhausted NK cells in advanced tumours and that MHC-I downregulation in tumours is closely associated with the induction of NK-cell exhaustion in both tumour-bearing mice and cancer patients.
23536636MelanomaInhibit immunityConcomitantly, tumor-specific CD4(+) T effector cells showed traits of chronic exhaustion, as evidenced by their high expression of the PD-1, TIM-3, 2B4, TIGIT, and LAG-3 inhibitory molecules. Although blockade of the PD-1/PD-L1 pathway with anti-PD-L1 Abs or depletion of tumor-specific regulatory T cells (Tregs) alone failed to reverse tumor recurrence, the combination of PD-L1 blockade with tumor-specific Treg depletion effectively mediated disease regression.
28408386Head and Neck CarcinomaInhibit immunity (T cell function)The frequency of PD-1 and TIM-3 expression was significantly increased in CD8+ TILs compared with CD8+ PBLs (P = 0.008 and P = 0.02, respectively). Indeed, the increased frequency of PD-1+?and TIM-3+?CD8+?TILs was inversely correlated with clinical outcome of cetuximab therapy
20819927Colon CarcinomaInhibit immunityWe have found that T cell immunoglobulin mucin (Tim) 3 is expressed on CD8(+) tumor-infiltrating lymphocytes (TILs) in mice bearing solid tumors.Tim-3(+)PD-1(+) TILs exhibit the most severe exhausted phenotype as defined by failure to proliferate and produce IL-2, TNF, and IFN-γ. We further find that combined targeting of the Tim-3 and PD-1 pathways is more effective in controlling tumor growth than targeting either pathway alone.
29506555Head and Neck CarcinomaInhibit immunityIn the transgenic HNSCC mouse model, blockade of TIM3 by the anti-TIM3 monoclonal antibody induced a reduction of CD4+CD25+Foxp3+ Tregs. Meanwhile, the population of TIM3+ Tregs was also decreased. The increased IFN-γ production on CD8+ T cells in anti-TIM3 treatment mice showed that the antitumor immune response was enhanced through suppression of these negative immune factors.
27872087Renal Cell CarcinomaInhibit immunity (T cell function)Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+ T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). The percentage of tumor-infiltrating CD8+ T cells coexpressing PD-1 and Tim-3 correlated with an aggressive phenotype and a larger tumor size at diagnosis.
21385853Acute Myeloid LeukemiaInhibit immunity (T cell function)Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. PD-1(+)Tim-3(+) CD8(+) T cells were deficient in their ability to produce IFN-γ, TNF-α, and IL-2 in response to PD-1 ligand (PDL1) and Tim-3 ligand (galectin-9) expressing AML cells. PD-1 knockout (KO), which were partially resistant to AML challenge, up-regulated Tim-3 during AML progression and such Tim-3(+)PD-1- KO CD8(+) T cells had reduced cytokine production. Therefore, combined PD-1/PDL1 and Tim-3/galectin-9 blockade may be beneficial in preventing CD8(+) T-cell exhaustion in patients with hematologic malignancies such as advanced AML.
28648905Hepatocellular CarcinomaInhibit immunity (T cell function)Expression of PD-1, TIM3, LAG3, and CTLA4 was significantly higher on CD8+and CD4+T cells isolated from HCC tissue than control tissue or blood. Compared with TIL that did not express these inhibitory receptors, CD8+and CD4+TIL that did express these receptors had higher levels of markers of activation, but similar or decreased levels of granzyme B and effector cytokines.
28102051Head and Neck Squamous Cell CarcinomaInhibit immunityIn this study, we report that TIM3 expression was significantly up-regulated in patients with HNSCC and associated with lymph node metastasis. We also characterized CD8+T cells and CD11b+CD33+myeloid-derived suppressor cells (MDSCs) in human HNSCC, and found that their expression was positively correlated with TIM3 expression. Treatment with anti-TIM3 monoclonal antibody effectively suppressed tumor growth through restoring effector T-cell function by targeting CD4+TIM3+cells and CD8+TIM3+cells and decreasing MDSCs.
20176801LymphomaInhibit immunityLymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. In vitro, Tim-3(+) ECs modulated T cell response to lymphoma surrogate antigens by suppressing activation of CD4(+) T lymphocytes through the activation of the interleukin-6-STAT3 pathway, inhibiting Th1 polarization, and providing protective immunity. In a lymphoma mouse model, Tim-3-expressing ECs promoted the onset, growth, and dissemination of lymphoma by inhibiting activation of CD4(+) T cells and Th1 polarization.
29858021Lung AdenocarcinomaInhibit immunityTIM-3 positivity was significantly associated with worse recurrence-free survival (RFS) (hazard ratio [HR], 2.32; 95% confidence interval [CI], 1.44-3.73, p = 0.001) and overall survival (OS) (HR, 2.04; 95% CI, 1.29-3.20, p = 0.002).
29712685Head and Neck CarcinomaInhibit immunityNovel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Tim-3+ Treg from human HNSCC TIL also displayed an effector-like phenotype, with more robust expression of CTLA-4, PD-1, CD39 and IFN-γ receptor. Tim-3+ Treg are functionally and phenotypically distinct in HNSCC TIL, and are highly effective at inhibiting T cell proliferation despite high PD-1 expression.
25220367Vulvar Intraepithelial NeoplasiaInhibit immunity (T cell function)The immune system prevents uncontrolled inflammation by expression of negative regulatory molecules, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), T cell immunoglobulin mucin 3 (TIM3) and programmed cell death 1 (PD1), suppressing T cell function (reviewed in Refs.
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HAVCR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HAVCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3160.394
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.270.855
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3470.748
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5290.257
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.020.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2340.463
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1360.778
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3280.817
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0830.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1840.898
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2970.895
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0030.987
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HAVCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HAVCR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HAVCR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HAVCR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HAVCR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HAVCR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HAVCR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHAVCR2
Namehepatitis A virus cellular receptor 2
Aliases Tim-3; TIM3; FLJ14428; TIMD3; CD366; T-cell immunoglobulin mucin family member 3; HAVcr-2; KIM-3; TIMD-3; T ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HAVCR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.